Table 2. Combination index between MEK inhibitors and conventional chemotherapeutic compounds.
| Cell line | Drug A | Drug B | Combination index | |
|---|---|---|---|---|
| Cytarabine | 0.34 | +++ | ||
| AS703026 | Daunorubicin | 0.31 | +++ | |
| Etoposide | >1.1 | - | ||
| Cytarabine | 0.49 | +++ | ||
| CMK | AZD6244 | Daunorubicin | <0.01 | +++ |
| Etoposide | 0.6 | +++ | ||
| Cytarabine | 0.32 | +++ | ||
| GSK1120212 | Daunorubicin | 0.14 | +++ | |
| Etoposide | >1.1 | - | ||
| Cytarabine | >1.1 | - | ||
| AS703026 | Daunorubicin | >1.1 | - | |
| Etoposide | >1.1 | - | ||
| Cytarabine | 0.24 | +++ | ||
| Kasumi1 | AZD6244 | Daunorubicin | 0.96 | ± |
| Etoposide | 0.24 | +++ | ||
| Cytarabine | >1.1 | - | ||
| GSK1120212 | Daunorubicin | >1.1 | - | |
| Etoposide | >1.1 | - | ||
| Cytarabine | 0.85 | ++ | ||
| AS703026 | Daunorubicin | 0.95 | ± | |
| Etoposide | 1.1 | ± | ||
| Cytarabine | 0.42 | +++ | ||
| MV-4-11 | AZD6244 | Daunorubicin | 0.47 | +++ |
| Etoposide | 0.52 | +++ | ||
| Cytarabine | >1.1 | - | ||
| GSK1120212 | Daunorubicin | 0.82 | ++ | |
| Etoposide | >1.1 | - | ||
| Cytarabine | 0.64 | +++ | ||
| AS703026 | Daunorubicin | 0.67 | +++ | |
| Etoposide | >1.1 | - | ||
| Cytarabine | 0.36 | +++ | ||
| THP-1 | AZD6244 | Daunorubicin | 0.43 | +++ |
| Etoposide | 0.51 | +++ | ||
| Cytarabine | >1.1 | - | ||
| GSK1120212 | Daunorubicin | >1.1 | - | |
| Etoposide | >1.1 | - | ||
Combination index was calculated from the ED50 using Chou-Talalay analysis in the CalcuSyn software; -, antagonism (>1.1); ±, additive (0.9–1.1); ++, moderate synergism (0.7–0.9); +++, synergism (0.3–0.7).